Chunxia Ai
Overview
Explore the profile of Chunxia Ai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, et al.
Elife
. 2023 Dec;
12.
PMID: 38127423
Germline CTLA-4 deficiency causes severe autoimmune diseases characterized by dysregulation of Foxp3 Tregs, hyper-activation of effector memory T cells, and variable forms autoimmune cytopenia including gradual loss of B cells....
2.
Muthana M, Du X, Liu M, Wang X, Wu W, Ai C, et al.
bioRxiv
. 2023 Mar;
PMID: 36909522
Germline CTLA-4 deficiency causes severe autoimmune diseases characterized by dysregulation of Foxp3 Tregs, hyper-activation of effector memory T cells, and variable forms autoimmune cytopenia including gradual loss of B cells....
3.
Liu M, Wang X, Du X, Wu W, Zhang Y, Zhang P, et al.
Sci Transl Med
. 2023 Mar;
15(685):eabm5663.
PMID: 36857433
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, not only elicit antitumor responses in a wide range of human cancers but also cause severe immune-related adverse events (irAEs), including...
4.
Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S, et al.
Signal Transduct Target Ther
. 2022 Jul;
7(1):224.
PMID: 35835736
No abstract available.
5.
Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, et al.
Cell Res
. 2019 Jul;
29(8):609-627.
PMID: 31267017
It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that...